Contact
QR code for the current URL

Story Box-ID: 304863

Protagen AG Otto-Hahn-Str. 15 44227 Dortmund, Germany http://www.protagen.de
Contact Ms Bettina Franz +49 231 97426300
Company logo of Protagen AG
Protagen AG

High Diagnostic Potential for Indication Specific Biomarkers

(PresseBox) (Dortmund, Germany / New Jersey, USA, )
The 1st user meeting on protein arrays in clinical applications was organized by Protagen, Germany, and focused on the increasing relevance of new markers and marker panels for drug development and therapy. Especially the potential of Protagen's UNIarray® platform technology for identification and validation of reliable biomarkers for indications like Multiple Sclerosis, Parkinsons Disease, Rheumatoid Arthritis, Heart Failure, and Prostate Cancer as well as the technological and biostatistical challenges in production and readout of protein array based multiplex diagnostics were discussed. Initiated by the DGKL [1] Working Group Clinical Proteomics and the MPC[2] , the "1st User Meeting on Protein Arrays for Clinical Applications" took place in the BioMedizinZentrum Dortmund on November 6th, 2009.

The current "Unmet Diagnostic Need" and the relevance of autoantibody signatures for advanced diagnostics and therapies in the indications mentioned above were impressively covered by the speakers' presentations.

Prof. Matthias Schneider, Head of the Rheumatology Department at the University Clinic Duesseldorf stated that "despite the fact that these novel autoantibody based serum diagnostics have not proven yet their robustness in routine applications, the results elaborated together with Protagen are already very impressive and promising".

Dr. Stefan Müllner, CEO of Protagen AG, added " In the last years we were able to establish a distinguished international network of clinical cooperation partners interested in our platform technology, and therefore are well equipped for the multicenter clinical validation of indication specific marker panels."

Dr. Jean-Marc Schlaeppi, Novartis Pharma AG, employs the UNIchip®-Technology of Protagen AG in preclinical development projects of therapeutic antibodies and explained after his talk "We are using these Chips for quantitative ranking of antibody development candidates based on the number of offtargetbinding events".

In summary, an interdisciplinary and comprehensive discussion was started to match the current status in protein array technologies and clinical requirements. A followup meeting is already planned for 2010.

[1] Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin
[2] Medical Proteome Center, Ruhr University Bochum

Protagen AG

Protagen AG is a leading provider of products, services and software solutions for protein research with sites in Dortmund, Germany, and Chester, New Jersey, USA. Technology innovations of Protagen are UNIclone®, a patented platform for development and use of protein expression libraries, and UNIchip®, a versatile and highly efficient family of products for the development of antibodies, as well as UNIarray®, unique technology base for the development of new diagnostics.
www.protagen.com

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.